Enlivex Ltd
1BT
Company Profile
Business description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Contact
14 Einstein Street
Weizmann Science Park
Ness Ziona7403618
ISRT: +972 86328500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
Amy Arnott explains how Morningstar’s stock ratings work.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.40 | 64.90 | -0.72% |
| CAC 40 | 8,211.31 | 5.47 | -0.07% |
| DAX 40 | 26,052.19 | 6.82 | 0.03% |
| Dow JONES (US) | 50,759.42 | 848.75 | -1.64% |
| FTSE 100 | 10,644.90 | 44.97 | -0.42% |
| HKSE | 23,294.75 | 213.42 | -0.91% |
| NASDAQ | 24,328.38 | 181.38 | -0.74% |
| Nikkei 225 | 59,024.28 | 163.85 | 0.28% |
| NZX 50 Index | 14,264.29 | 42.67 | -0.30% |
| S&P 500 | 7,340.53 | 76.06 | -1.03% |
| S&P/ASX 200 | 8,821.80 | 61.40 | -0.69% |
| SSE Composite Index | 3,587.83 | 3.25 | 0.09% |